Ausgabe 5/2011
Inhalt (26 Artikel)
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting
Athanassios P. Kyritsis, Victor A. Levin
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
Chee M. Ng, A. Patnaik, M. Beeram, C. C. Lin, C. H. Takimoto
Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent
Carol E. Green, Robert Swezey, James Bakke, Walter Shinn, Anna Furimsky, Naveen Bejugam, Gita N. Shankar, Ling Jong, Izet M. Kapetanovic
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
Kenjiro Aogi, Masayuki Yoshida, Yoshiaki Sagara, Shunji Kamigaki, Minoru Okazaki, Jumpei Funai, Toshio Fujimoto, Masakazu Toi, Toshiaki Saeki, Shigemitsu Takashima
H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein
Ning Wei, Hua Sun, Fengpeng Wang, Gengtao Liu
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma
Mario Airoldi, Pietro Gabriele, Anna Maria Gabriele, Massimiliano Garzaro, Luca Raimondo, Fulvia Pedani, Fabio Beatrice, Giancarlo Pecorari, Carlo Giordano
Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals
Ghada M. Suddek
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations
Howard A. Burris III, David Berman, Bindu Murthy, Suzanne Jones
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
Inge R. H. M. Konings, Stefan Sleijfer, Ron H. J. Mathijssen, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Linda M. van Dam, Erik A. C. Wiemer, Jaap Verweij, Walter J. Loos
Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects
Riyo Enomoto, Chika Koshiba, Chie Suzuki, Eibai Lee
Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase
Sunny Guin, Qi Ma, Snehal Padhye, Yong-Qing Zhou, Hang-Ping Yao, Ming-Hai Wang
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis
C. A. C. X. Medeiros, R. F. C. Leitão, R. N. Macedo, D. R. M. M. Barboza, A. S. Gomes, N. A. P. Nogueira, N. M. N. Alencar, R. A. Ribeiro, G. A. C. Brito
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors
Yutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study
T. Waddell, S. Gollins, W. Soe, J. Valle, J. Allen, D. Bentley, J. Morris, A. Lloyd, R. Swindell, M. B. Taylor, M. P. Saunders
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
Haruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura
Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells
Maiko Suzuki, Manabu Endo, Fumiaki Shinohara, Seishi Echigo, Hidemi Rikiishi
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
M. Joerger, A. Templeton, D. Köberle, H. Engler, W. F. Riesen, B. Thürlimann
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity
Kashyap Patel, Steve S. F. Choy, Kevin O. Hicks, Teresa J. Melink, Nicholas H. G. Holford, William R. Wilson
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
Anja Frömberg, Daniela Gutsch, Daniel Schulze, Claudia Vollbracht, Gabriele Weiss, Frank Czubayko, Achim Aigner
Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death
Bettina M. Kaminski, Andreas Weigert, Bernhard Brüne, Marco Schumacher, Uwe Wenzel, Dieter Steinhilber, Jürgen Stein, Sandra Ulrich
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity
Michele Basso, Anna Modoni, Daniele Spada, Alessandra Cassano, Giovanni Schinzari, Mauro Lo Monaco, Davide Quaranta, Pietro Attilio Tonali, Carlo Barone
The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
Susanna B. Park, Cindy S-Y. Lin, Arun V. Krishnan, Matthew C. Kiernan
Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells
Jorge Humberto Tapia-Pérez, Elmar Kirches, Christian Mawrin, Raimund Firsching, Thomas Schneider
A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer
Christos Chouaid, Faith Nathan, Kristine Pemberton, Thomas Morris
Erratum to: Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice
Yongchuan Gu, Christopher P. Guise, Kashyap Patel, Maria R. Abbattista, Jie Li, Xueying Sun, Graham J. Atwell, Maruta Boyd, Adam V. Patterson, William R. Wilson